CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 20 8089 7893 support@capital.com

交易 Cerevel Therapeutics Holdings, Inc. - CERE CFD

26.95
0.04%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 0.11
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.030779%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.013666%
隔夜费时间 22:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* 26.94
开盘价* 25.72
1 年变化* -4.56%
日范围* 25.72 - 27.24
52 周范围 19.86-41.46
平均交易量（10 天） 403.76K
平均交易量（3 个月) 10.83M
市值 5.47B
市盈率 -100.00K
流通股 156.32M
收入 N/A
EPS -2.13
股息（收益率 %） N/A
贝塔 -100.00K
下一个财报发布日期 Feb 22, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low
Jun 29, 2022 26.95 1.81 7.20% 25.14 27.30 25.14
Jun 28, 2022 26.94 -0.93 -3.34% 27.87 29.13 26.80
Jun 27, 2022 28.99 0.89 3.17% 28.10 29.70 27.49
Jun 24, 2022 28.08 -0.17 -0.60% 28.25 29.09 27.63
Jun 23, 2022 28.54 3.28 12.98% 25.26 28.60 25.26
Jun 22, 2022 26.05 1.34 5.42% 24.71 26.24 24.71
Jun 21, 2022 25.15 -0.32 -1.26% 25.47 25.47 24.03
Jun 17, 2022 23.86 0.20 0.85% 23.66 24.42 23.16
Jun 16, 2022 22.85 -1.18 -4.91% 24.03 24.03 22.07
Jun 15, 2022 24.53 0.31 1.28% 24.22 24.87 23.33
Jun 14, 2022 24.22 0.64 2.71% 23.58 25.12 23.54
Jun 13, 2022 23.87 -0.71 -2.89% 24.58 24.67 23.20
Jun 10, 2022 25.82 -0.27 -1.03% 26.09 27.04 25.60
Jun 9, 2022 27.99 0.51 1.86% 27.48 28.92 27.48
Jun 8, 2022 28.49 1.30 4.78% 27.19 29.41 27.19
Jun 7, 2022 28.72 3.24 12.72% 25.48 28.84 25.48
Jun 6, 2022 25.86 -1.88 -6.78% 27.74 28.32 25.13
Jun 3, 2022 27.78 1.02 3.81% 26.76 28.51 26.76
Jun 2, 2022 26.98 1.06 4.09% 25.92 27.80 25.30
Jun 1, 2022 26.37 0.40 1.54% 25.97 26.76 25.02

Cerevel Therapeutics Holdings, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • 年度
  • 每季度
2019 2020 2021
总收入 0 0 0
营业收入 0 -149.116 -220.098
摊薄调整 0
摊薄净收入 0 -148.271 -225.334
总营业费用 149.116 220.098
销售/一般/行政费用，总计 45.813 58.243
研究与开发 103.303 161.855
利息收入（费用），非经营净值 0.224 0.157
其他，净值 -3.274 -5.393
税前净收入 -152.166 -225.334
税后净收入 -152.142 -225.334
未计算非常项目前的净收益 -152.142 -225.334
净收入 -152.142 -225.334
Total Adjustments to Net Income 3.871 0
普通股股东可获收益 (不含非经常性项目) -148.271 -225.334
普通股股东可获收益 (含非經常性項目) -148.271 -225.334
摊薄后加权平均股 73.6433 136.577
扣除特别项目的每股摊薄盈利 -2.01337 -1.64987
每股正常摊薄盈利 -2.01337 -1.64987
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
总收入 0 0 0 0 0
总营业费用 50.571 50.51 54.527 64.49 72.53
销售/一般/行政费用，总计 14.01 13.216 14.368 16.649 17.507
研究与开发 36.561 37.294 40.159 47.841 55.023
营业收入 -50.571 -50.51 -54.527 -64.49 -72.53
利息收入（费用），非经营净值 0.015 0.01 0.013 0.119 0.295
其他，净值 -0.425 -2.739 -7.545 5.316 3.941
税前净收入 -50.981 -53.239 -62.059 -59.055 -68.294
税后净收入 -50.981 -53.239 -62.059 -59.055 -68.294
未计算非常项目前的净收益 -50.981 -53.239 -62.059 -59.055 -68.294
净收入 -50.981 -53.239 -62.059 -59.055 -68.294
普通股股东可获收益 (不含非经常性项目) -50.981 -53.239 -62.059 -59.055 -68.294
普通股股东可获收益 (含非經常性項目) -50.981 -53.239 -62.059 -59.055 -68.294
摊薄净收入 -50.981 -53.239 -62.059 -59.055 -68.294
摊薄后加权平均股 127.226 127.482 144.022 147.392 147.985
扣除特别项目的每股摊薄盈利 -0.40071 -0.41762 -0.4309 -0.40067 -0.46149
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.40071 -0.41762 -0.4309 -0.40067 -0.46149
  • 年度
  • 每季度
2019 2020 2021
流动资产总额 390.56 578.017
现金和短期投资 383.623 565.688
现金等价物 383.623 193.018
Prepaid Expenses 6.777 11.6
Other Current Assets, Total 0.16 0.729
Total Assets 445.273 688.919
Property/Plant/Equipment, Total - Net 48.624 51.7
Property/Plant/Equipment, Total - Gross 48.706 54.266
Accumulated Depreciation, Total -0.082 -2.566
Other Long Term Assets, Total 6.089 6.933
Total Current Liabilities 29.548 42.538
Accounts Payable 4.993 11.298
Accrued Expenses 24.282 30.865
Notes Payable/Short Term Debt 0 0
Other Current Liabilities, Total 0.273 0.375
Total Liabilities 60.753 110.19
Total Long Term Debt 0 33.54
Other Liabilities, Total 31.205 34.112
Total Equity 384.52 578.729
Common Stock 0.013 0.015
Additional Paid-In Capital 775.417 1195.94
Retained Earnings (Accumulated Deficit) -390.91 -616.244
Total Liabilities & Shareholders’ Equity 445.273 688.919
Total Common Shares Outstanding 127.124 147.72
短期投资 372.67
Long Term Investments 52.269
Long Term Debt 33.54
Other Equity, Total -0.986
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
流动资产总额 349.811 331.782 675.029 578.017 553.55
现金和短期投资 343.287 327.06 669.676 565.688 542.944
现金等价物 343.287 327.06 669.676 193.018 91.764
Prepaid Expenses 6.362 4.597 5.257 11.6 10.004
Other Current Assets, Total 0.162 0.125 0.096 0.729 0.602
Total Assets 408.104 391.004 733.48 688.919 618.552
Property/Plant/Equipment, Total - Net 51.784 51.92 51.98 51.7 52.663
Property/Plant/Equipment, Total - Gross 51.876 52.552 53.526 54.266 56.299
Accumulated Depreciation, Total -0.092 -0.632 -1.546 -2.566 -3.636
Other Long Term Assets, Total 6.509 7.302 6.471 6.933 4.411
Total Current Liabilities 34.151 29.257 30.8 42.538 35.318
Accounts Payable 7.755 4.986 5.445 11.298 8.183
Accrued Expenses 26.241 23.939 24.928 30.865 26.442
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.155 0.332 0.427 0.375 0.693
Total Liabilities 68.068 97.117 104.4 110.19 97.053
Total Long Term Debt 0 32.242 38.612 33.54 28.324
Other Liabilities, Total 33.917 35.618 34.988 34.112 33.411
Total Equity 340.036 293.887 629.08 578.729 521.499
Common Stock 0.013 0.013 0.015 0.015 0.015
Additional Paid-In Capital 781.914 789.004 1186.79 1195.94 1207.36
Retained Earnings (Accumulated Deficit) -441.891 -495.13 -557.189 -616.244 -684.538
Total Liabilities & Shareholders’ Equity 408.104 391.004 733.48 688.919 618.552
Total Common Shares Outstanding 127.325 127.585 147.136 147.72 148.183
Long Term Debt 32.242 38.612 33.54 28.324
Other Equity, Total -0.533 -0.986 -1.334
短期投资 372.67 451.18
Long Term Investments 52.269 7.928
  • 年度
  • 每季度
2019 2020 2021
净收入/起跑线 -152.142 -225.334
经营活动产生的现金 -117.802 -178.546
经营活动产生的现金 0.397 2.731
非现金物品 16.236 28.516
营运资金的变化 17.707 15.541
投资活动产生的现金 -18.892 -435.661
资本支出 -18.892 -10.503
融资活动产生的现金 440.835 423.602
融资现金流项目 440.835 -0.355
现金净变化 304.141 -190.605
其他投资现金流量项目，总计 -425.158
股票的发行（报废），净额 392.707
债务的发行（退还），净额 31.25
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -50.981 -104.22 -166.279 -225.334 -68.294
Cash From Operating Activities -36.418 -82.026 -125.802 -178.546 -67.648
Cash From Operating Activities 0.063 0.664 1.644 2.731 1.118
Non-Cash Items 6.377 14.084 27.551 28.516 4.935
Changes in Working Capital 8.123 7.446 11.282 15.541 -5.407
Cash From Investing Activities -4.66 -8.243 -9.431 -435.661 -38.542
Capital Expenditures -4.66 -8.243 -9.431 -10.503 -2.197
Cash From Financing Activities 0.742 33.706 421.286 423.602 2.603
Issuance (Retirement) of Stock, Net 0.742 2.571 390.036 392.707 2.854
Net Change in Cash -40.336 -56.563 286.053 -190.605 -103.587
Financing Cash Flow Items -0.115 0 -0.355 -0.251
Issuance (Retirement) of Debt, Net 31.25 31.25 31.25
Other Investing Cash Flow Items, Total -425.158 -36.345
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Bain Capital Private Equity, LP Private Equity 38.7867 60632356 0 2022-09-30 LOW
Pfizer Inc Corporation 17.4954 27349211 0 2022-08-16 MED
Fidelity Management & Research Company LLC Investment Advisor 14.5762 22785810 1072862 2022-09-30 LOW
Perceptive Advisors LLC Private Equity 4.1656 6511727 0 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7506 5863050 861581 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.0327 4740842 -1555066 2022-09-30 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 2.1195 3313333 200000 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.025 3165508 43098 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.7395 2719272 304798 2022-09-30 LOW
Rock Springs Capital Management LP Hedge Fund 1.5987 2499148 732007 2022-09-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 1.2803 2001437 2001437 2022-09-30 HIGH
Invus Public Equities Advisors, LLC Investment Advisor 1.2794 2000000 500000 2022-09-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 0.8847 1382960 1369554 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7256 1134261 81971 2022-09-30 LOW
Lord, Abbett & Co. LLC Investment Advisor 0.6947 1085956 82992 2022-09-30 MED
Point72 Asset Management, L.P. Hedge Fund 0.6936 1084240 881940 2022-09-30 HIGH
Alkeon Capital Management LLC Investment Advisor/Hedge Fund 0.6291 983408 -35667 2022-09-30 LOW
Hood River Capital Management LLC Investment Advisor 0.5735 896572 473322 2022-09-30 MED
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.4714 736972 11220 2022-09-30 LOW
Novalis LifeSciences LLC Private Equity 0.4052 633350 0 2022-03-31

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group
+500000+

交易者

93000+

每月活跃客户

$57000000+

每月投资额

$31000000+

每月提取金额

交易計算器

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

貿易佣金
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
杠杆
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

Cerevel Therapeutics Holdings, Inc. Company profile

关于 Cerevel Therapeutics Holdings Inc.

Cerevel Therapeutics Holdings, Inc.是一家处于临床阶段的生物制药公司。 公司将对疾病相关生物学和大脑神经回路的理解与化学和中枢神经系统（CNS）、受体药理学相结合，发现和设计新疗法。 公司正在从事神经科学疾病的新疗法的开发，包括精神分裂症、癫痫和帕金森病。 公司的候选产品包括CVL-231、Darigabat、Tavapadon、CVL-871和CVL-936。 公司的候选产品CVL-231用于治疗精神分裂症。 其Darigabat用于治疗癫痫和焦虑症。 其Tavapadon是一种多巴胺D1/D5部分激动剂，用于治疗早期和晚期帕金森病。 其候选产品CVL-871用于治疗痴呆症相关的冷漠症。 其CVL-936用于治疗物质使用障碍（SUD）。

Industry: Bio Therapeutic Drugs

222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US

收入报表

  • Annual
  • Quarterly

人们也观看

XRP/USD

0.41 Price
+1.790% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 0.00437

US100

12,709.50 Price
+1.950% 1D Chg, %
多头隔夜费 -0.0187%
空头隔夜费 0.0075%
隔夜费时间 22:00 (UTC)
价差 1.8

Oil - Crude

77.71 Price
+4.070% 1D Chg, %
多头隔夜费 -0.0221%
空头隔夜费 0.0069%
隔夜费时间 22:00 (UTC)
价差 0.03

BTC/USD

23,280.75 Price
+1.520% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 66.00

还在找一位您可以信任的经纪商吗？

加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易